Sign In
Buy ABBV
$224.93
+7.86 (+3.62%)
At Close: Jun 04, 2026
My Portfolio April Update - 7 Buys
04:24am, Thursday, 05'th May 2022 Seeking Alpha
This month I added capital to 7 of my holdings and dividends were up YoY. Click here to know my buys and the ones I'm looking to add in May.
These Warren Buffett Dividend Stocks Can Make You $12,800 in Passive Income
09:52am, Wednesday, 04'th May 2022 The Motley Fool
You'll need to invest $100,000 in each stock to generate five-figure annual income.
IYH: Diversified Healthcare ETF Suitable For Short Term Investment
04:24am, Tuesday, 03'rd May 2022 Seeking Alpha
The IYH ETF has posted strong price returns over the medium and long term, but generated 1% yield. Read why I'll prefer to make IYH a trading instrument.
Here's Why This Analyst Is On Sidelines Despite European Approval Of Myovant's Relugolix For Prostate Cancer
07:49pm, Monday, 02'nd May 2022 Benzinga
Myovant Sciences Ltd (NYSE: MYOV) received European approval for Orgovyx (relugolix, 120 mg) for advanced hormone-sensitive prostate cancer, and SVB Securities think Orgovyx could be a ~$1 billion
Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?
10:20am, Monday, 02'nd May 2022 Zacks Investment Research
Smart Beta ETF report for FXH
Want $2,000 in Passive Income? Invest $10,000 in This Cathie Wood Dividend Stock and Wait 5 Years
03:00pm, Saturday, 30'th Apr 2022 The Motley Fool
This dividend stock is one of the few holdings that Cathie Wood and Warren Buffett have in common.
The Near Perfect Portfolio For The Good Times And Bad
01:00pm, Saturday, 30'th Apr 2022 Seeking Alpha
With index investing, there's no escape from a roller coaster ride. For most people, especially retirees, it's very difficult to tolerate large and deep drawdowns.
AbbVie's Q1 Good News That Investors Could Be Missing
09:57am, Saturday, 30'th Apr 2022 The Motley Fool
The big drugmaker's results were disappointing, but there were several things to like in its report.
AbbVie (ABBV) Q1 2022 Earnings Call Transcript
09:00am, Saturday, 30'th Apr 2022 The Motley Fool
ABBV earnings call for the period ending March 31, 2022.
Why AbbVie's Shares Dropped 10.5% Friday
08:46pm, Friday, 29'th Apr 2022 The Motley Fool
Some of the pharmaceutical company's sales trends concerned investors.
AbbVie (ABBV) Q1 Earnings Top, Competition Rises for Imbruvica
03:20pm, Friday, 29'th Apr 2022 Zacks Investment Research
AbbVie (ABBV) beats estimates for first-quarter 2022 earnings while missing the same for sales. Strong demand for immunology drugs, aesthetics and cosmetics drives sales. Shares decline.
'So bad, it's good.' This beleaguered stock market has one big asset on its side, say strategists.
01:49pm, Friday, 29'th Apr 2022 MarketWatch
It has been a rough April for investors, but there is still reason for cheer, says our call of the day.
The 3 Best ETFs for Dividends
01:10pm, Friday, 29'th Apr 2022 The Motley Fool
Investors don't have to do any actual stock picking to plug into good passive income with these ETFs.
AbbVie (ABBV) Tops Q1 Earnings Estimates
01:05pm, Friday, 29'th Apr 2022 Zacks Investment Research
AbbVie (ABBV) delivered earnings and revenue surprises of 0.32% and 0.09%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stocks Q1 Earnings Due on Apr 29: BMY, ABBV, AZN
02:53pm, Thursday, 28'th Apr 2022 Zacks Investment Research
Let us take a look at what is in store for BMY, ABBV, and AZN that are scheduled to report on Apr 29.
